Product Code: BRCA(VARIANT_INTERPRETATION)-25
Free
Deadline to order: N/A
This scheme is an online competency assessment for the classification of breast cancer (BRCA) and homologous recombination repair (HRR) genes
This scheme is applicable to all individuals who classify the pathogenicity of BRCA (BRCA1 and BRCA2) and other HRR gene (PALB2, ATM, RAD15C and CHEK2) variants.
Registration for the next run will be advertised in Autumn 2024. There are two runs per year (autumn and spring) comprising online competency assessment and access to educational webinars by international experts. Delivered in conjunction with GenQA.
Not applicable
Not applicable
Online (virtual) case(s)
No
The aim of this module is to provide an online competency
assessment for the classification of HRR gene variants related to breast /
ovarian and prostate cancer. This assessment is open to individuals who
classify the pathogenicity of variants and aimed to provide assurance of
competence to accurately achieve this in the most up-to-date manner.
For each ONLINE assessment, participants receive six variants to classify within four weeks. Participants can choose to classify some or all of the variants. For each variant classification submitted, participants should also provide the criteria evidence for their classification.
The classifications and evidence are pre-agreed by an
international panel of experts.
To
register to participate, please use this link HERE.
Online only- no samples provided for this scheme
On completion of the assessment, all participants will receive:
This assessment delivered in conjunction with GenQA and is sponsored through an unrestricted
educational grant from AstraZeneca and MSD, and there is no fee to participate.
Details of the next available assessment are provided upon registration, along with registration details for educational webinars.
Relevant resources:
ACMG Variant classification guidelines
ACGS 2020 Best Practice Guidelines for Variant Classification
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.